Taraxol

Taraxol (Taraxerol): A Comprehensive Reference

1. Identity, Chemical Profile, and Common Names

Taraxol is a common informal name for the phytochemical systematically designated taraxerol. Taraxerol, with the IUPAC name (3β)-D-Friedoolean-14-en-3-ol, is a pentacyclic triterpenoid. The compound is also known by a few other synonymous names, including isoolean-14-en-3β-ol, skimmiol, alnulin, and tiliadin. Structurally, taraxerol is an oleanan-3-ol with an alpha-methyl substituent at position 13, a missing methyl group at position 14, and a double bond between positions 14 and 15. Its CAS registry number is 127-22-0.

Taraxerol, an oleanane-type pentacyclic triterpene, is one of the natural compounds that have been investigated extensively for its potential utilization in drug development. Its chemical structure was first elucidated by Beaton et al. (1955), who identified that the oleanane-3-ol lacks the methyl group at position 14, with an α-methyl substituent at position 13 and a double bond between positions 14 and 15.

Relationship to Other Taraxacum-Derived Triterpenoids

Taraxol/taraxerol is one of several structurally related pentacyclic triterpenes found in dandelion and related plants. Dandelion contains abundant triterpenoids, including compounds like taraxasterol, pseudotaraxasterol, lupeol, and their acetates; pentacyclic triterpenoids are the predominant type in dandelion. These related compounds — taraxasterol, pseudotaraxasterol, taraxerone, and taraxerol — share a common biosynthetic origin but differ in their skeletal arrangements and functional groups, and each has a distinct pharmacological profile. This article focuses on taraxerol (taraxol) specifically, while noting relevant comparisons to its close congener taraxasterol where the science overlaps.

Natural Sources and Botanical Distribution

Taraxerol is a naturally occurring pentacyclic triterpenoid that exists in various higher plants, including Taraxacum officinale (Asteraceae), Alnus glutinosa (Betulaceae), Litsea dealbata (Lauraceae), Skimmia spp. (Rutaceae), Dorstenia spp. (Moraceae), Maytenus spp. (Celastraceae), and Alchornea latifolia (Euphorbiaceae). Additional plants containing taraxerol include Hypericum perforatum, Clitoria ternatea, Mangifera indica, and Strobilanthes crispus. Members of the Asteraceae family comprise the greatest number of taraxerol-containing taxa, followed by the Euphorbiaceae and Malvaceae families.

Taraxerol was named "alnulin" when it was first isolated in 1923 from the bark of the grey alder (Alnus incana L.) by Zellner and Röglsperger. It also had the name "skimmiol" when Takeda and Yosiki isolated it from Skimmia (Rutaceae). The compound was later isolated and characterized in dandelion (Taraxacum officinale), which became its most widely studied botanical source.

The roots of T. officinale contain the triterpenes β-amyrin, taraxasterol, and taraxerol, as well as the sterols sitosterin, stigmasterin, and phytosterin. Several compounds have been identified from various organs of the dandelion plant to which medicinal activity has been attributed, primarily comprising various triterpenes (α-/β-amyrin, lupeol, taraxerol, taraxasterol, amidiol, faradiol), sterols, and phenolics (caffeic acid, phenylacetic acid, and chlorogenic acids).

Common Preparations and Commercial Forms

Taraxol/taraxerol is not typically marketed as an isolated supplement in mainstream commerce; rather, it reaches consumers as a constituent of broader dandelion preparations. These include:

• Dried root powder and root extracts (standardized or non-standardized), used in capsules and tablets
• Hydroethanolic tinctures prepared from leaves or roots
• Aqueous infusions and decoctions of the root or whole herb
• Roasted root preparations as a coffee substitute

A variety of preparations of the raw material exist: fresh and dried raw materials are used to make extracts, tinctures, decoctions, infusions, wrap compresses, syrups, and even wine or coffee substitutes. For research and pharmaceutical development purposes, taraxerol is also available as an isolated phytochemical standard at varying degrees of purity. Various biotechnological approaches have been established to produce this compound using in vitro techniques.

2. Traditional and Historical Use

Chinese Medicine

In China, Taraxacum (dandelion, Pugongying in Chinese) is originally documented for medicinal use in the Newly Revised Materia Medica during the Tang dynasty (618–907 AD) and was compiled for dietary purposes in the Materia Medica for Famine during the Ming dynasty (1364–1644 AD). Dandelion has been extensively utilized in traditional Chinese medicine since the 7th century. Traditional Chinese medicine (TCM) uses dandelion, often in combination with other herbs, to treat hepatitis, to enhance immune response to upper respiratory tract infections, bronchitis, or pneumonia; in TCM, the species Taraxacum mongolicum (pu gong ying) is commonly used. In Chinese terms, the plant is seen as having cooling and cleansing effects, and it is used in toxic, inflamed, and chronically infected conditions — those classified as damp heat problems in particular. In the 2020 edition of the Chinese Pharmacopoeia, the genus Taraxacum (T. mongolicum Hand.-Mazz. and T. officinale F.H.Wigg.) is extensively utilized for its heat-clearing, detoxifying, anti-inflammatory, and nodule-dispersing properties.

Arabian and Middle Eastern Medicine

The therapeutic use of dandelion has been mentioned by Arabian, Native American, Chinese and Ayurvedic Medicine. Medieval Arabian physicians, including those of the 10th–11th centuries, documented dandelion as a remedy for liver and digestive complaints. The plant was known in Arabic as tarakhshaqun, a term that may have etymologically influenced the Latinized genus name Taraxacum.

European Herbalism

In Europe, dandelion's edible and medicinal properties began to be acknowledged and applied during the Middle Ages. In ethnomedical practice, dandelion has been used as a diuretic, laxative, anti-inflammatory remedy, and digestive aid. In the traditional societies of Central-Eastern Europe, dandelion is a source of food and medicinal raw materials. The vast experience of rural communities in Central-Eastern Europe concerning the medicinal applications of common dandelion has developed through centuries. European herbalists of the medieval and early modern periods prepared the root and leaves as infusions and decoctions principally for liver disorders, gallbladder complaints, kidney stones, and as a general spring tonic.

Ayurvedic and Native American Use

Taraxacum officinale, belonging to the Asteraceae family, is a prominent medicinal plant of Arabian, American, Chinese, and Ayurvedic systems of medicine, and has been used for health purposes since ancient times — including for hepatic disorders and breast and uterine cancers. In Ayurvedic tradition, the whole plant was employed as a bitter tonic (tikta dravya) to stimulate digestion and liver function. Native American peoples of several nations used related Taraxacum species as food and prepared decoctions for kidney disorders and general health maintenance.

Summary of Traditional Preparation and Intended Use

Across cultures and time periods, the most consistent traditional applications of dandelion preparations containing taraxerol were:

• Liver and gallbladder support (choleretic and hepatoprotective use)
• Diuretic and kidney-cleansing preparations
• Digestive stimulation and appetite improvement (via bitter principles)
• Anti-inflammatory and "blood purifying" tonics
• Treatment of skin conditions, jaundice, and fever

Traditionally, dandelion is used to treat various ailments such as migraines, cardiac complaints, jaundice, fever, liver and kidney disorders, and hepatitis. It must be noted that these traditions refer to whole-plant preparations; the specific contribution of taraxerol to these traditional effects was not understood until modern phytochemical analysis.

3. Key Constituents and Biosynthesis

Biosynthetic Pathway

Taraxerol is a pentacyclic triterpenoid that is actively produced by some higher plants as part of a defense mechanism. Its biosynthesis occurs through the mevalonate pathway in the cytosol, in which dimethylallyl diphosphate (DMAPP) and isopentyl pyrophosphate (IPP) are first produced, followed by squalene. Squalene is the primary precursor for the synthesis of triterpenoids, including taraxerol, β-amyrin, and lupeol, which are catalyzed by taraxerol synthase. The enzyme taraxerol synthase — an oxidosqualene cyclase (OSC) — cyclizes 2,3-oxidosqualene through a multi-ring cascade reaction to yield the characteristic D-friedooleanane skeleton.

Co-occurring Bioactive Compounds in the Source Plant

Because taraxerol is almost never encountered in pure isolated form in commercial preparations, its pharmacological context is inseparable from the broader phytochemical matrix of its primary botanical source. Dandelions contain a wide range of bioactive compounds, such as polyphenols, phytosterols, flavonoids, carotenoids, terpenes, and coumarins, whose biological activities are actively explored in various areas of human health, some constituents having synergistic activities, including antioxidant, antimicrobial, anti-inflammatory, and anticancer activities.

• Triterpenes: taraxerol (taraxol), taraxasterol, pseudotaraxasterol, β-amyrin, lupeol, amidiol, faradiol, and their acetate esters
• Sesquiterpene lactones: taraxacin, taraxinic acid derivatives (responsible for bitterness and choleretic effects)
• Phenolic acids: caffeic acid, chlorogenic acid, cichoric acid
• Flavonoids: luteolin, luteolin-7-glucoside, quercetin, rutin
• Polysaccharides: inulin (up to 25% in the root by some analyses)
• Sterols: β-sitosterol, stigmasterol, phytosterol
• Carotenoids: taraxanthin (in flowers)

The primary therapeutic actions of dandelion are believed to be due to the bitter principle of taraxacin, various terpenoids, inulin, and its high concentration of nutrients, especially choline. Other constituents of dandelion that may contribute to its pharmacologic effects are resins, pectin, taraxanthin (a carotenoid pigment in the flowers), fatty acids, and flavonoids.

4. Mechanisms of Action

Anti-inflammatory Mechanisms

Taraxerol is a pentacyclic triterpenoid found in medicinal plants, fruits, and vegetables, and is a potent anti-inflammatory agent. Research has explained the molecular mechanism of the anti-inflammatory effects of taraxerol and its interactions with many molecular targets, including NF-κB, MAPKs, and COX.

The NF-κB (nuclear factor kappa-B) pathway is central to its anti-inflammatory action. Research has shown that taraxerol alleviates acute inflammatory responses by inhibiting the NF-κB signaling pathway. NF-κB is a key transcription factor that plays an important role in the inflammatory process; under normal circumstances it is suppressed in the cytoplasm, but under inflammatory stimulation, it is activated and transferred to the nucleus, inducing the expression of pro-inflammatory cytokines. Research has found that taraxerol can directly interfere with the activation of NF-κB, preventing it from entering the nucleus and reducing the production of pro-inflammatory cytokines.

Studies have shown that taraxerol can reduce the expression of inflammation-related enzymes such as COX-2 and iNOS, which are often overactivated during acute inflammation. Taraxerol acetate has demonstrated significant inhibitory effects against both COX-1 (IC₅₀ value of 116.3 ± 0.03 µM) and COX-2 (IC₅₀ value of 94.7 ± 0.02 µM) enzymes in an in vitro enzyme inhibition assay, showing a significant role in the regulation of COX expression.

Beyond NF-κB, the anti-inflammatory effects of taraxerol involve interactions with NF-κB, MAPKs, and COX, and also encompass the effects of taraxerol on oxidative stress, cell function, and inflammatory cell signaling. A key study found that taraxerol significantly inhibited lipopolysaccharide (LPS)-induced production of interleukin-1β (IL-1β), IL-6, and tumor necrosis factor-alpha (TNF-α) by interfering with the activation of TAK1 and Akt, thus preventing NF-κB activation.

Antioxidant Mechanisms

The effects of taraxerol on oxidative stress, cell function, and inflammatory cell signaling have been comprehensively described. Taraxerol has been shown to exert antioxidant effects through modulation of endogenous antioxidant enzyme systems. Pretreatment with taraxerol increased myocardial activity of SOD (superoxide dismutase) and GPx (glutathione peroxidase), leading to significant reductions in MDA (malondialdehyde), TNF-α, and IL-6.

Pro-apoptotic and Anticancer Mechanisms

Taraxerol affects the mitochondrial apoptotic pathway through the release of cytochrome c to the cytosol and activation of caspases. Taraxerol enhanced ROS levels and attenuated the mitochondrial membrane potential (ΔΨm) in HeLa cells; it induced apoptosis mainly via the mitochondrial pathway including the release of cytochrome c to the cytosol and activation of caspases 9 and 3, and anti-poly (ADP-ribose) polymerase (PARP). Taraxerol could induce the down-regulation of the anti-apoptotic protein Bcl-2 and up-regulation of pro-apoptotic protein Bax, and suppressed the PI3K/Akt signaling pathway.

Glucose Metabolism and Metabolic Mechanisms

In metabolic contexts, taraxerol has been studied for modulating glucose transport. Taraxerol demonstrated strong binding affinities and strong interactions with C-Jun N-terminal Kinase, Lamin A/C, and Human Aldose Reductase, with these interactions indicating a function to reduce inflammation and treat complications of diabetes.

5. Scientific Evidence by Area of Use

5.1 Anti-inflammatory Activity

Preclinical (in vitro and animal) evidence: The anti-inflammatory properties of taraxerol are among the most extensively studied. A key preclinical study by Khanra et al. (2017) evaluated taraxerol isolated from Abroma augusta leaf in both cell-based and animal models of inflammation. The study by Khanra, Dewanjee, Dua, and Bhattacharjee, published in Biomedicine & Pharmacotherapy (2017, vol. 88:1469–1478), demonstrated that taraxerol, a pentacyclic triterpene from Abroma augusta leaf, attenuates acute inflammation via inhibition of NF-κB signaling.

Yao et al. demonstrated in an LPS-stimulated macrophage model that taraxerol inhibits inflammatory responses through suppression of TAK1 and Akt activation (International Immunopharmacology, 2013). That study found that taraxerol significantly inhibited LPS-induced production of IL-1β, IL-6, and TNF-α by interfering with the activation of TAK1 and Akt, thus preventing NF-κB activation.

The overall findings highlight the need for additional research to completely understand the therapeutic potential and clinical applications of taraxerol in the treatment of inflammatory diseases.

Evidence strength: Preclinical only (cell culture and rodent models). No published human clinical trials on isolated taraxerol for any inflammatory condition have been identified in the peer-reviewed literature. The evidence is preliminary and mechanistically suggestive.

5.2 Anticancer Activity

Preclinical evidence: Several in vitro and limited in vivo studies address taraxerol's antiproliferative and pro-apoptotic effects in cancer cell lines.

• HeLa cells (cervical cancer): In an experimental study investigating the effect of taraxerol on HeLa cells, viability was tested by the MTT assay; apoptosis was analyzed by DAPI staining and flow cytometry; ROS and mitochondrial membrane potential were also determined. Taraxerol enhanced ROS levels and attenuated the mitochondrial membrane potential (ΔΨm), and induced apoptosis mainly via the mitochondrial pathway including the release of cytochrome c to the cytosol.
• HepG2 and A431 cells (liver and epidermoid carcinoma): Taraxerol has shown in vitro cytotoxic activity against HepG2 and A431 human cancer cell lines and potent inhibition of topoisomerase II.
• Human glioblastoma (U87 cells): A study demonstrated that taraxerol acetate induces potent anticancer effects in U87 cells in in vitro and in vivo experiments, mediated via the induction of apoptosis, autophagy, and cell cycle arrest. The effects on cell cycle phase distribution, cell cycle-associated proteins, autophagy, DNA fragmentation, and cell migration were assessed.
• Gastric cancer (AGS cells): Tan et al. (2011) examined the effects of taraxerol and taraxeryl acetate on cell cycle and apoptosis of the human gastric epithelial cell line AGS (Chinese Journal of Integrative Medicine, 2011:9:638–642).

Taraxerol has been reported to remarkably inhibit TPA-induced tumor promotion on mouse spontaneous mammary tumors. In Radix Codonopsis research, taraxerol was identified as one of the key anticancer components; these compounds exert anti-cancer effects through various mechanisms, such as inducing tumor cell apoptosis and inhibiting tumor cell proliferation.

Evidence strength: All evidence to date is in vitro (cell culture) and limited in vivo (animal/xenograft) only. There are no human clinical trials of isolated taraxerol for any cancer. The preclinical data are mechanistically interesting but cannot be extrapolated to clinical benefit without controlled human studies.

5.3 Cardioprotective Activity

Preclinical (animal) evidence: Researchers investigated the potential cardioprotective effects of taraxerol utilizing an isoproterenol (ISO)-induced cardiotoxicity model among Sprague Dawley rats. Subcutaneous tissue injections of 5.25 mg/kg or 8.5 mg/kg ISO were administered over two consecutive days to induce cardiac injury, and five groups were formed including a normal control, ISO control, amlodipine (5 mg/kg/day), and various doses of taraxerol. The results showed that treatment significantly reduced cardiac marker enzymes; pretreatment with taraxerol increased myocardial activity of SOD and GPx, leading to significant reductions in serum CK-MB levels along with MDA, TNF-α, and IL-6. Histopathological analysis supported these observations, as treated animals had less cellular infiltration compared to untreated ones. These findings suggest that oral administration of taraxerol could potentially protect hearts from ISO-caused damage by increasing endogenous antioxidant concentrations while decreasing pro-inflammatory cytokines.

Evidence strength: Animal model only; no human clinical trials. Evidence is preliminary and limited to a single rodent model of chemically induced cardiac toxicity.

5.4 Neuroprotective and Cognitive Effects

Taraxerol attracted wide interest among researchers due to its significant capabilities in modern pharmacology, such as its ability to act as an anti-tumor, anti-microbial, and anti-inflammatory agent, and in the treatment of Alzheimer's disease. A study by Berté et al. (2018) examined taraxerol as a possible therapeutic agent on memory impairments and Alzheimer's disease, assessing effects against scopolamine and streptozotocin-induced cognitive dysfunctions in animal models (Steroids, 2018, 132:5–11).

In computational pharmacokinetic studies, taraxerol (along with alpha-amyrin and friedelin) was found to penetrate through the blood-brain barrier, while the remaining tested compounds did so poorly. This finding lends mechanistic plausibility to central nervous system activity, though it requires validation in experimental and clinical models.

Evidence strength: Animal pharmacology and in silico data only. No human clinical trials exist for taraxerol in neurological or cognitive conditions. Evidence is at an early exploratory stage.

5.5 Antidiabetic and Metabolic Activity

A study by Sangeetha et al. (2010) reported that 3β-taraxerol derived from Mangifera indica acted as a PI3K-dependent dual activator of glucose transport and glycogen synthesis in 3T3-L1 adipocytes (Biochimica et Biophysica Acta, 2010, 1800:359–366). Taraxerol showed strong interactions with C-Jun N-terminal Kinase, Lamin A/C, and Human Aldose Reductase; these interactions indicate a function to reduce inflammation and treat complications of diabetes.

Evidence strength: Preclinical (cell culture and in silico) only. No clinical trials in humans have been conducted. The mechanism is biologically plausible but unproven in humans.

5.6 Hepatoprotective Activity

The broader Taraxacum officinale literature supports hepatoprotective activity, with taraxerol as one of the implicated constituents. Preclinical studies have reported that extracts of this plant protect against liver damage induced by toxic agents such as alcohol, carbon tetrachloride, and paracetamol. Among the most relevant and predominant bioactive compounds of T. officinale is taraxasterol, which modulates inflammatory and oxidative stress pathways, helping to prevent liver damage. Taraxerol contributes to the overall triterpenoid fraction identified in hepatoprotective studies, though its individual contribution relative to co-occurring triterpenes has not been fully separated in the published literature.

Evidence strength: For whole-plant extracts: moderate preclinical evidence. For taraxerol as an isolated hepatoprotective compound: preliminary/indirect preclinical only.

5.7 Antimicrobial Activity

Taraxacum officinale is reported for various pharmacological activities including antimicrobial effects. Taraxerol attracted wide interest among researchers due to its significant capabilities in modern pharmacology, including its ability to act as an anti-microbial agent. Studies from Strobilanthes and other species have demonstrated anti-inflammatory and antimicrobial activities of triterpenoids including taraxerol against bacterial and fungal strains in vitro, though species-specific minimum inhibitory concentration data for isolated taraxerol are sparse in the publicly accessible peer-reviewed literature.

Evidence strength: Preliminary in vitro evidence only. No clinical studies exist.

5.8 Diuretic Activity

The diuretic effect is one of the best-studied activities of dandelion preparations at a human level, though published studies use leaf extracts rather than isolated taraxerol. In one pilot human study involving 17 subjects, administration of a fresh leaf hydroethanolic dandelion leaf extract at a dose of 8 ml led to a significant increase in the frequency of urination in the five-hour period after the first dose. There was also a significant increase in the excretion ratio in the five-hour period after the second dose of extract. The third dose failed to change any of the measured parameters.

Evidence strength: One small, short-duration human pilot study for whole leaf extract. Evidence for isolated taraxerol contributing to this diuretic effect: absent.

6. Body Systems and Health Areas Associated with Taraxol/Taraxerol

Based on the peer-reviewed literature, taraxerol and its source plant preparations have been studied in relation to the following body systems and health areas:

• Immune system and inflammation: Modulation of NF-κB, MAPK, COX-1/2, iNOS, and pro-inflammatory cytokine pathways
• Cardiovascular system: Antioxidant and anti-inflammatory effects in models of myocardial injury
• Hepatic system: Hepatoprotection against toxic insults (studied at plant extract level)
• Oncology: Pro-apoptotic, antiproliferative, and cell-cycle-arresting effects in cancer cell lines
• Central nervous system: Preliminary exploration in Alzheimer's and cognitive impairment animal models
• Metabolic/endocrine system: Glucose transport modulation, interaction with aldose reductase
• Renal system: Diuretic activity (for whole-leaf preparations)
• Digestive system: Bitter-principle-mediated choleretic and digestive effects

Taraxacum officinale is reported for various pharmacological activities such as antidiabetic, antioxidant, hepatoprotective, diuretic, anti-inflammatory, neuroprotective, antidepressant, antimicrobial, and immunostimulatory activities. The plant provides broad varieties of phytochemicals possessing specific biological activities like sesquiterpene lactones with anti-inflammatory and antimicrobial properties, triterpenes with anti-atherosclerotic effects, phenolic acids with antioxidant and immunostimulatory properties, coumarins with antitumor, anti-inflammatory, antimicrobial, anticoagulant properties, and flavonoids with antioxidant activity.

7. Dosage Forms and Reported Dosages

No established or recommended clinical dosage exists for isolated taraxerol. The dosages reported in published scientific studies concern either isolated taraxerol in preclinical models or whole dandelion plant preparations in clinical and preclinical contexts.

Isolated Taraxerol (Preclinical Animal Studies)

• In the isoproterenol-induced cardiotoxicity model, cardiac injury was induced with subcutaneous injections of 5.25 mg/kg or 8.5 mg/kg isoproterenol over two consecutive days; the taraxerol-treated groups received various oral doses alongside a positive control of amlodipine at 5 mg/kg/day.
• In the HeLa cell apoptosis study, cells were incubated with taraxerol at concentrations of 0, 20, 40, and 80 µM for 12 hours.

Whole Dandelion Preparations (Human Studies)

• In a human pilot diuretic study involving 17 subjects, a fresh leaf hydroethanolic dandelion leaf extract was administered at a dose of 8 ml.
• Dried root preparations have been used in European herbal medicine practice, with the British Pharmacopoeia setting quality standards. The British Pharmacopoeia sets a minimum bitterness value of 100 for the root.

Overall Dosage Evidence

The limited human clinical study and pharmacokinetics information lead to the thought that well-designed human clinical studies should be the focus and opportunity for future research to truly understand the efficacy function and health benefit of dandelion for its application in medicine and health food. In the absence of clinical trial data for isolated taraxerol, no evidence-based dosage recommendation for supplementation can be established.

8. Safety Considerations and Drug Interactions

Safety Profile of Taraxerol (Isolated Compound)

Taraxerol is a pentacyclic triterpenoid found in medicinal plants, fruits, and vegetables. Formal toxicology studies on isolated taraxerol in humans are absent from the published literature. Computational toxicology analyses have been conducted:

In a computational study validating top-ranked drug molecules (including taraxerol), ADME, toxicity, and drug bioavailability properties were assessed. The ADME analysis of taraxerol reveals promising properties and notable challenges for potential therapeutic use; all three compounds including taraxerol exhibit proper Caco-2 permeability, indicating their potential for adequate intestinal absorption.

In pharmacokinetic prediction analyses, taraxerol was found to penetrate through the blood-brain barrier. Further testing of top compounds' pharmacokinetics data revealed that they might make suitable medication candidates because of their low or non-existent toxicity to humans — though this is in silico evidence only.

For the related triterpene taraxasterol: no toxic effects of taraxasterol were observed in mice that received doses as high as 10 mg/kg. This finding may aid in pharmacokinetic studies of taraxasterol in humans and other animals; however, more clinical studies are necessary on the metabolism, bioavailability, and safety of taraxasterol to support its applications in pharmaceuticals and medicine. This safety caveat applies equally to taraxerol, for which the clinical data are at the same nascent stage.

Safety of Whole Dandelion Preparations

Dandelion (Taraxacum officinale) as a whole-plant preparation has a generally favorable safety record in traditional use. The principal known safety concerns, documented in the phytomedicinal literature, include:

• Allergic contact dermatitis: Dandelion belongs to the Asteraceae (Compositae) family. Individuals sensitive to other members of this family (e.g., chrysanthemum, ragweed, marigold) may experience cross-reactive allergic reactions to dandelion preparations.
• Diuretic interactions: Dandelion leaf preparations exert measurable diuretic effects and may potentiate the action of diuretic medications, potentially causing excessive fluid loss or electrolyte imbalance in susceptible individuals.
• Anticoagulant interactions: The inhibitory effect on platelet aggregation in humans by ethanolic extracts of dandelion root (Taraxacum officinale F.H. Wigg.) was examined; the extracts showed dose-dependent inhibition of platelet aggregation, with maximum inhibition of 85% at a concentration equivalent to 0.04 g dried root/mL human platelet-rich plasma (PRP), regardless of whether platelet aggregation was induced by arachidonic acid or collagen. The fraction enriched in triterpenes and steroids (Mr > 10,000) showed 80% inhibition of platelet aggregation at a concentration equivalent to 0.04 g raw material/mL PRP. This in vitro platelet aggregation inhibition suggests potential interaction with anticoagulant or antiplatelet medications, though the clinical significance is not established.
• Diabetes medication interactions: Given preclinical evidence of glucose transport modulation by taraxerol and related triterpenes, and the anti-diabetic properties attributed to dandelion preparations, caution and monitoring are warranted when such preparations are used concomitantly with antidiabetic drugs.
• Lithium: The diuretic action of dandelion preparations may reduce lithium clearance, potentially increasing serum lithium levels — a well-recognized pharmacokinetic concern with diuretics as a class.
• Bioavailability limitations: As a highly lipophilic triterpene, taraxerol faces substantial bioavailability challenges common to its structural class, including poor aqueous solubility and extensive first-pass metabolism. In computational analysis, taraxerol's synthetic accessibility was scored at 6.17, reflecting the structural complexity that also affects its pharmaceutical optimization. In silico permeability data are encouraging, but validated human pharmacokinetic data are not yet available.

Overall Evidence Gap

More animal and clinical studies are required on the metabolism, bioavailability, and safety of taraxol/taraxerol-related triterpenoids to support their applications in pharmaceuticals and medicine. The research on taraxerol addresses limitations and obstacles in current research and highlights the need for additional work to completely understand the therapeutic potential and clinical applications of taraxerol in the treatment of inflammatory and other diseases.

9. Evidence Limitations and Research Gaps

The scientific literature on taraxerol (taraxol) presents several significant limitations that must be acknowledged:

• Absence of human clinical trials: As of the available literature, there are no published randomized controlled trials or Phase I/II clinical studies evaluating isolated taraxerol in any human population for any indication.
• Isolation methodology variability: Different studies use taraxerol from different plant sources (dandelion, Abroma augusta, Mangifera indica, etc.), and the purity and characterization methods vary, limiting direct comparison.
• Absence of validated pharmacokinetics in humans: Parameters including oral bioavailability, plasma half-life, tissue distribution, and metabolic pathways in humans are not established in the experimental literature.
• Confounding from whole-plant extracts: Much of the traditional use and some of the clinical data (particularly the diuretic study) pertains to whole-plant preparations; attribution of specific effects to taraxerol is not validated.
• The limited human clinical study and pharmacokinetics information present a clear research opportunity for well-designed human clinical studies to truly understand the efficacy function and health benefit for application in medicine and health food.

References

• Khoo HE et al. "The Biosynthesis and Medicinal Properties of Taraxerol." Biomedicines 2022, 10(4):807. PMC9025716.
• Jiao F et al. "The phytochemical and pharmacological profile of taraxasterol." Frontiers in Pharmacology 2022. doi:10.3389/fphar.2022.927365
• Jiao F et al. "The phytochemical and pharmacological profile of taraxasterol." PMC9386448.
• Wikipedia: Taraxerol. Chemical identity, synonyms, and natural sources.
• Encyclopedia MDPI: Taraxerol entry. Biosynthesis and medicinal properties.
• Dulf FV et al. "Bioactive Compounds from Vegetal Organs of Taraxacum Species (Dandelion) with Biomedical Applications: A Review." PMC11764760.
• Li Y et al. "Taraxerol Induces Cell Apoptosis through A Mitochondria-Mediated Pathway in HeLa Cells." Cell Journal 2017. PMC5572297.
• Hong JF et al. "Anticancer activity of taraxerol acetate in human glioblastoma cells and a mouse xenograft model." Molecular Medicine Reports 2016.
• Khalid A et al. "Effects of Taraxerol on Oxidative and Inflammatory Mediators in Isoproterenol-Induced Cardiotoxicity in an Animal Model." Molecules 2023. PMC10224333.
• Rehman M et al. "Taraxerol: A Promising Natural Product in the Management of Inflammation." The Natural Products Journal 2024. Bentham Science.
• Li X et al. "Taraxasterol Inhibits LPS-Induced Inflammatory Response in BV2 Microglia Cells by Activating LXRα." Frontiers in Pharmacology 2018. PMC5893773.
• "Unveiling the genus Taraxacum: From folk medicine to chemodiversity-driven pharmacological and toxicological outcomes — A systematic review." Journal of Ethnopharmacology 2026.
• Yao X et al. "Taraxacum: Phytochemistry and health benefits." Chinese Herbal Medicines 2018.
• Szopa A et al. "Dandelion (Taraxacum officinale L.) as a Source of Biologically Active Compounds Supporting the Therapy of Co-Existing Diseases in Metabolic Syndrome." PMC9498421.
• Piwowarski JP et al. "Multilateral Use of Dandelion in Folk Medicine of Central-Eastern Europe." PMC11723127.
• Vlase AM et al. "New Approaches on the Anti-Inflammatory and Cardioprotective Properties of Taraxacum officinale Tincture." PMC10053582.
• Sharma P et al. "Review on natural bioactive compounds of Taraxacum officinale Weber: a potential anticancer plant." Pharmaceutics and Pharmacology 2024. Oxford Academic.
• "The Role of Dandelion (Taraxacum officinale) in Liver Health and Hepatoprotective Properties." PMC12299503.
• Khan MA et al. "Unveiling the phytopharmacological insights of Taraxacum officinale." Discover Plants 2025. Springer Nature.
• Herbal Reality: Dandelion (Taraxacum officinale): Benefits, Safety, Uses. Evidence narrative review.
• "Supramolecular environment and androgen receptor binding of taraxerol: from molecular structure to potential bioactivity function." Rendiconti Lincei. Scienze Fisiche e Naturali 2025. Springer Nature.
• "Exploring potential phytocompounds from black cumin as drug molecules against SARS-CoV-2 infections through bioinformatics analysis." PLOS ONE 2026.
• "New prospects in oncotherapy: bioactive compounds from Taraxacum officinale." PMC12334242.
• Renna M. "Taraxacum officinale L. in leukemia and lymphoma: current knowledge and prospects for horticulture." PMC12819242.
• "Antioxidant and antimicrobial activities of Dandelion root extract (Taraxacum officinale) and its cytotoxic effect on MDA-MB-231 breast cancer cells." Discover Applied Sciences 2025. Springer Nature.